Our finding that our newly developed ceramide analogs effectively increase the efficacy of FasL-mediated target colon cancer cell lysis by tumor-specific CTLs suggests that these ceramide analogs may have the potential to increase CTL efficacy against immune suppressive cancers. Here, FASLG is linked to colonic neoplasm.